News

Novo Nordisk's shares rose by 5.4% on Thursday as investors turned more positive about the Danish drugmaker's prospects ...
Novo Nordisk (NYSE: NVO) -- the original Ozempic stock -- jumped higher again Thursday after announcing results from a weight ...
Wegovy has been a hugely popular treatment since the Food and Drug Administration (FDA) approved it for weight loss in ...
Trial results showed the "Wegovy pill" led to average weight reduction of 16.6% after 64 weeks, Novo Nordisk said.
Medicare and Medicaid coverage of GLP-1 weight loss drugs could be just what the doctor ordered for these two struggling ...
It’s unclear how much such a pill would cost, but Novo Nordisk’s Ozempic and Wegovy shots currently go for several hundred ...
Novo Nordisk (NVO) said Wednesday that oral semaglutide 25 mg (Wegovy in a pill) delivered 16.6% weight loss in people with ...
Novo Nordisk has a strong financial position and portfolio of weight-loss and diabetes treatments. See why NVO’s stock dip ...
Canadians now have a comprehensive, convenient home delivery option for Ozempic® and Wegovy® prescriptions MISSISSAUGA, ON, ...
Novo Nordisk's shares rise as Phase III trial shows its oral Wegovy pill achieves significant weight loss, offering a new ...
“Results showed that if all participants adhered to treatment, average weight loss of 16.6% was achieved by people taking ...
Novo Nordisk said that patients taking a pill form of Wegovy in a clinical trial lost about as much weight as those who get ...